Australia- and U.S.-based biotechnology company Vaxxas, which is seeking to commercialize a needle-free vaccination technology, has added Dan Devine as chief business officer and general counsel.
Devine started his career at the Wall Street law firm Dewey Ballantine before spending more than two decades in the biopharmaceutical industry, including a stint at Pfizer, where he headed an international business development group. He also founded, led and took public Patrys, a Melbourne-based developer of anti-cancer antibodies.
For the past decade, he has been a consultant to Australian-based Mesoblast, which develops medicines to treat complex inflammatory diseases resistant to conventional care.
“The company’s technology platform and the vaccine products that it enables offer a rare opportunity to fundamentally change the way vaccines are developed and distributed worldwide,” Devine said in a statement. “Given lessons learned from the COVID-19 pandemic, I couldn’t think of a better time than now to dedicate myself to that effort.”
Vaxxas launched in 2011 and is based in Melbourne, Australia, and Cambridge, Massachusetts.